2,173 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
GILD Gilead Sciences, Inc. $72.78 $94.35B Uptrend
Article Searches
Shionogi's Strong Core Offers More Capital Return Possibilities https://seekingalpha.com/article/4233693-shionogis-strong-core-offers-capital-return-possibilities?source=feed_sector_healthcare Jan 16, 2019 -
Why AbbVie Believes In Life After (Humira's) Death https://seekingalpha.com/article/4233472-abbvie-believes-life-humiras-death?source=feed_sector_healthcare Jan 15, 2019 - ABBV has been mired in a bear market, in large part due to worse-than-expected competition to Humira from biosimilars in the EU.U.S. biosimilars to Humira will enter in 2023, though a competitor is tr
Is 2019 The Turnaround Year For Gilead Sciences? https://seekingalpha.com/article/4233225-2019-turnaround-year-gilead-sciences?source=feed_sector_healthcare Jan 14, 2019 - Following precipitous revenue losses attributable to its portfolio of HCV medicines, Gilead finds itself in improving financial straits.2019 will see the release of pivotal data from Phase III clinica
Agenus Gets A Grant: A Good Opportunity To Buy https://seekingalpha.com/article/4232871-agenus-gets-grant-good-opportunity-buy?source=feed_sector_healthcare Jan 11, 2019 - Agenus received a $1 million grant from the Bill & Melinda Gates Foundation.The company’s lead candidates showed successful phase I/II results.The unique portfolio of antibodies, vaccines, adjuvants,
Road To Financial Independence: My December 100-Stock Portfolio Review https://seekingalpha.com/article/4232446-road-financial-independence-december-100-stock-portfolio-review?source=feed_all_articles Jan 09, 2019 - The year closed with a bang, with stock markets tanking, dividend income rising and portfolio restructuring.I outline portfolio composition by sector and portfolio weight for every holding.I have deci
Gilead Is Gearing Release Of NASH Results Soon, But Other Deals Are Still Rolling In https://seekingalpha.com/article/4232316-gilead-gearing-release-nash-results-soon-deals-still-rolling?source=feed_sector_healthcare Jan 09, 2019 - Gilead Sciences continues to make a strong push for partnering with or acquiring NASH companies to solidify a stronghold in this space.Results from two selonerstib studies treating patients with NASH,
Where Will M&A Strike Next Across Biotech? https://seekingalpha.com/article/4232266-will-m-strike-next-across-biotech?source=feed_sector_healthcare Jan 09, 2019 - After a dearth of purchase transactions across the industry, M&A has returned in a big way early in 2019 to the biotech space.Both Celgene and Loxo Oncology have been bought out for healthy premiums e
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus http://www.zacks.com/stock/news/346497/biotech-stock-roundup-loxo-celg-gain-jp-morgan-healthcare-conference-in-focus?cid=CS-ZC-FT-346497 Jan 09, 2019 - It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
7 Things to Expect for Gilead Sciences in 2019 https://www.fool.com/investing/2019/01/08/7-things-to-expect-for-gilead-sciences-in-2019.aspx?source=iedfolrf0000001 Jan 08, 2019 - The big biotech's executives spill the beans on plans for the new year at the J.P. Morgan Healthcare Conference.
Book Entry: Review: ‘The Edge of Anarchy’ Offers Lessons From the Gilded Age https://www.nytimes.com/2019/01/07/business/dealbook/review-the-edge-of-anarchy.html?partner=rss&emc=rss Jan 07, 2019 - The current political and economic environment makes Jack Kelly’s examination of the events that ended the Gilded Age both timely and urgent.

Pages: 123456...218

Page 1>

Related Companies

Name Exchange Price Mkt Cap
BIIB Biogen Inc. NASDAQ $334.44 $67.37B
AMGN Amgen Inc. NASDAQ $200.81 $129.98B
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Gilead Sciences
GILD - Google Finance https://www.google.com/finance?q=GILD Industry related info and international coverage Summary News
GILD - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=GILD Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options